Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
PLoS One
; 14(1): e0210593, 2019.
Article
en En
| MEDLINE
| ID: mdl-30608991
ABSTRACT
[This corrects the article DOI 10.1371/journal.pone.0164646.].
Texto completo:
1
Bases de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
Idioma:
En
Revista:
PLoS One
Asunto de la revista:
CIENCIA
/
MEDICINA
Año:
2019
Tipo del documento:
Article